Antibody response to influenza vaccination in the elderly: a quantitative review.
By Katherine Goodwin, Cécile Viboud, L. Simonsen. Vaccine, 2006
1,089 citations recorded by the source corpus.
Subfields: Epidemiology, Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/723d87abdd26c56707053aafec1cfca2cda9665b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- R. Aspinall
- J. Glanville
- J. Mannick
- Q. Qi
- David K. Shay
- Anthony E. Fiore
- G. Del Giudice
- Yi Liu
Citations in the corpus
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial (2020, neutral): “This fact holds true for vaccines such as for influenza, for which pre-existing immune memory exists, 27 and vaccines that induce primary immune responses, such as hepatitis B. 28 Other adenovirus-vector platforms against SARS-CoV-2 have either shown reduced immunogenicity in an older age group 11…”
- Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. (2009, background): “Adults aged ≥65 years typically have a diminished immune response to influenza vaccination compared with young healthy adults, suggesting that immunity might be of shorter duration (although still extending through one influenza season) (155,156).”
- B-cell responses to vaccination at the extremes of age (2009, background): “The ability of influenza vaccine to induce protection is related to age, with an efficacy between 70% and 90% in those under 65 years of age, but of 30% to 40% at best for those over 65 years of ag”
- Diversity and clonal selection in the human T-cell repertoire (2014, background): “Moreover, immune responses to vaccination are dramatically reduced (7).”
- mTOR inhibition improves immune function in the elderly (2014, background): “Adults 65 years of age and older account for 90% of influenza-related deaths in the United States and also have a lower antibody response to influenza vaccination as compared to younger adults (5, 6).”